Acta Neuropharmacologica››2013,Vol. 3››Issue (6): 44-47.
Previous ArticlesNext Articles
WANG Jin
Online:2013-12-26Published:2014-06-27About author:王金，男，讲师，硕士；研究方向：中药新药研究开发；Tel：+86-0313-4029305；E-mail：wangjinzym@163.comSupported by:
河北省卫生厅资助项目（No.20110173），河北省教育厅资助项目（No.Z2011304）
CLC Number:
WANG Jin.Non-motor Symptoms of Parkinson’s Disease[J]. Acta Neuropharmacologica, 2013, 3(6): 44-47.
| [1] Sara Varanese, Zoe Birnbaum, Roger Rossi, et al. Treatment of advanced Parkinson’s disease[J].Parkinsons Dis, 2011, 2010: 480260. [2] Cynthia L Commella. Sleep disturbances in Parkinson’s disease[J] .Curr Neurol Neurosci Rep, 2003, 10(3):173–180. [3] I Eisensehr, R linke, S Noachtar, et al. Reduced striatal dopamine transports in idiopathic rapid eye movement sleep behaviour disorder.comparasion with parkinson’s disease[J]. Brain, 2000, 123(Pt6): 1155-1160. [4] B F Boeve, M H Silber, J E Parisi, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism[J]. Neurology, 2003, 61(1): 40–45. [5] J F Gagnon, M A Bedard, M L Fantini, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease [J]. Neurology, 2002, 59(4):585–589. [6] R D Abbott, G W Ross, L R White, et al. Excessive daytime sleepiness and the future risk of Parkinson’s disease [J]. Mov Disord, 2005, 20(10):S101. [7] Thomas Müller. Drug therapy in patients with Parkinson’s disease [J]. Translational Neurodegeneration, 2012, 1:10. [8] Sze-Ee Soh, Meq E Morris, Jennifer L McGinley. Determinants of health-related quality of life in Parkinson’s disease: a systematic review [J].Parkinsonism Relat Disord, 2011, 17(1):1-9. [9] J Schwarz, P Odin, C Buhmann, et al. Depression in Parkinson’s disease [J]. J Neurol, 2011, 258(suppl 2):S336-S338. [10] Laura Marsh. Neuropsychiatric aspects of Parkinson’s disease [J]. Psychosmatics, 2000, 41(1):15-23. [11] 周晓雯，苏朝芬，罗焕敏. 线粒体与神经退行性疾病[J].神经药理学报，2011，1(3)：41-46. [12] 薛占霞，彭亮. 情感性精神障碍疾病治疗药物的研究现状[J].神经药理学报，2011，1(3)：55-64. [13] Ziemssen Tjalf, Heinz Reichmann. Non-motor dysfunction in Parkinson’s disease [J]. Parkinsonism related disorder, 2007, 13(6):323332. [14] I H Richard, R B Schiffer, R Kurlan. Anxiety and Parkinson’s disease [J]. J Neuropsychiatry Clin Neurosci, 1996, 8:383-392. [15] Manmohan Mehndiratta, Rohit K Garg, Sanjay Pandey. Nonmotor symptom complex of Parkinson's disease--an under-recognized entity [J]. J Assoc Physicians India, 2011, 59: 302-308. [16] E C Lauterbach, R C Duvoisin. Anxiety disorders in familial parkinsonism [J]. Am J Psychiatry, 1992, 148(2):274. [17] Jennifer G Goldman. New thoughts on thought disorders in Parkinson’s disease: review of current research strategies and challenges [J]. Parkinsons Dis, 2011, 2011:675630. [18] 王新，于谭方，王平. 帕金森病患者非运动症状的研究进展 [J].国际神经病学神经外科杂志，2011（38）2:139-142. [19] Angie A Kehagia, Roger A Baker, Trevor W Robbins. Neuropsychological and clinical heterogeneity of congnitive impariment and dementia in patients with Parkinson’s disease [J]. Lancet Neurol, 2010, 9(12): 1200-1213. [20] Murat Emre. Demetia associated with Parkinson’s disease [J]. Lancet Neurol, 2003, 2(4): 229–237. [21] Lehana Yeo, Rajindra Singh, Mohan Gundeti, et al. Urinary tract dysfunction in Parkinson’s disease: a review [J]. Int Urol Nephrol, 2012, 44(2):415-424. [22] Michael S Okun, Benjamin L Walter, William M McDonald, et al. Beneficial effects of testosterone replacement for the non motor symptoms of Parkinson’s disease [J]. Arch Neurol, 2002, 59(11):1750-1753. [23] Francesca Romana Pezzella, Carlo Colosimo, Nicola Vanacore, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease [J].Mov Disord, 2005, 20(1):77-81. [24] R D Abbott, H Petrovitch, L R White, et al. Frequency of bowel movements and future risk of Parkinson’s disease[J]. Neurology, 2001, 57(3):456-462. [25] Quinn NP, Koller WC, Lang AE, et al. Painful Parkinson’s disease [J].Lancet, 1996, 1:1366-1369. [26] W Poewe. Nonmotor symptoms in Parkinson’s disease. In: Jankovic J, Tolosa E, eds. Parkinson’s disease and movement disorders [M]. 5th. Philadelphia: Lippincott Williams and Wilkins, 2007:67-76. [27] Andrew Siderowf, Danna Jdennings, James Connolly, et al. Risk factors for Parkinson’s disease and impaired olfaction in relatives of patients with Parkinson’s disease[J]. Mov Disord, 2007, 22(15):2249-2255. [28] G Webster Ross, Helen Petrovitch, Robert D Abbott, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease [J]. Ann Neurol, 2008, 63(2):167-173. |
| [1] | LI Hui, YANG Jin-shui, XUE Qian.A Case of Huntington's Disease with Involuntary Movements of the Limbs as the First Symptom Combined with Dysarthria in the Early Stages of the Disease[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(6): 31-. |
| [2] | ZHANG Yuan-qing, LIN Yu, HUANG Li.Study on the Effects of Vitamin D on DNA Methylation in Alzheimer's Disease Cell Models[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(6): 39-. |
| [3] | ZHAO Yu-ting, YIN Hong-yan, GUO Chun-yan.Explore the Mechanism of Paeoniae Radix Alba Delaying Alzheimer's Disease Based on Network Pharmacology and Molecular Docking[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(5): 1-. |
| [4] | ZHANG Xin, YAO Si-fan, MA Meng-fan, SHEN Li-xia.Recent Progress in the Metabolomics of Alzheimer's Disease[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(5): 47-. |
| [5] | YAO Si-fan, ZHANG Xin, SHEN Li-xia.Effects of Tau Protein on Mitochondrial Function in Alzheimer's Disease[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(4): 54-. |
| [6] | WANG Tian-xu, LIU Ci, CUI Yong-yuan, ZHANG Xin, WU Miao-miao, SHEN Li-xia.Explore the Mechanism of Quercetin in the Treatment of Alzheimer's Disease by Network Pharmacology and Molecular Docking[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(2): 31-. |
| [7] | YIN Hong-yan, YOU Si-han, GUO Chun-yan.Research Progress of Core Markers and Other Markers of Alzheimer's Disease[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(6): 45-. |
| [8] | ZHU Jing-yi , FAN Jian-chun, YU Ai-mei.Research Status on the Neuroprotective Effect of Probucol[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(6): 50-. |
| [9] | .Exploring the Effect and Mechanism of Pterostilbene on Alzheimer’s Disease Based on Network Pharmacology[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(5): 1-. |
| [10] | BAI Jing-ru, YOU Si-han, YIN Hong-yan, YANG Song-rui, GUO Chun-yan.Predicting the Target of Peach Kernel in the Treatment of Parkinson's Disease Based on Network Pharmacology[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(3): 31-. |
| [11] | GUO Bao, LIU Zi-ming, JING Yong-shuai, ZHANG Dan-shen.Correlation Between Wnt Signaling Pathway and Alzheimer's Disease and Its Targets[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(1): 56-. |
| [12] | SI Wen-ying, HOU Yu-qing, SUN Xiao-jing, MENG Xian-yong, DONG Xiao-hua.Gene Therapy for Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(6): 51-56. |
| [13] | ZHANG Zhi-qing, ZHANG Yong-cai, LIU Lin-xuan, LI Ren-qing, LIU Ji-jia, DU Jing-kao, JIANG Bei, WEI Huiping, SU Li-ning.Bioinformatics Analysis of the Relationship between Exosomal ceRNA Regulatory Network and Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(4): 23-40. |
| [14] | CAI Yu-shan, ZHAO Shuai.Role of PPARβ/δ in Neurodegenerative Diseases[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(4): 41-48. |
| [15] | LV Xue-ying, ZHANG Zheng, LUO Huan-min.The Blood-Brain Barrier and Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(4): 58-64. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
